ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för LFM-A13. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

20 träffar

Bibliografisk träff 2020-12-01

The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.

Rozkiewicz D, Hermanowicz JM, Tankiewicz-Kwedlo A, Sieklucka B, Pawlak K, Czarnomysy R, Bielawski K, Surazynski A, Kalafut J, Przybyszewska A, Koda M, Jakubowska K, Rivero-Muller A, Pawlak D.

J Enzyme Inhib Med Chem · research-article; journal article · DOI 10.1080/14756366.2020.1818738

Bibliografisk träff 2020-06-19

Negative Regulation of Tec Kinase Alleviates LPS-Induced Acute Kidney Injury in Mice via theTLR4/NF-<i>κ</i>B Signaling Pathway.

Zhang W, Zhou P, Jiang X, Fan Z, Xu X, Wang F.

Biomed Res Int · research-article; journal article · DOI 10.1155/2020/3152043

Bibliografisk träff 2019-02-14

Effects of Tec Tyrosine Kinase Inhibition on the Inflammatory Response of Severe Acute Pancreatitis-Associated Acute Lung Injury in Mice.

Meng Y, Sha S, Yang J, Ren H.

Dig Dis Sci · research support, non-u.s. gov't; journal article · DOI 10.1007/s10620-019-05524-7

Bibliografisk träff 2018-04-23

Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer.

Tankiewicz-Kwedlo A, Hermanowicz JM, Pawlak K, Czarnomysy R, Bielawski K, Prokop I, Pawlak D.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms19041262

Bibliografisk träff 2018-01-25

Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.

Tankiewicz-Kwedlo A, Hermanowicz JM, Domaniewski T, Pawlak K, Rusak M, Pryczynicz A, Surazynski A, Kaminski T, Kazberuk A, Pawlak D.

Br J Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bph.14099

Bibliografisk träff 2017-11-15

LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.

Sahin K, Tuzcu M, Yabas M, Orhan C, Sahin N, Ozercan IH.

Invest New Drugs · research support, non-u.s. gov't; journal article · DOI 10.1007/s10637-017-0540-2

Bibliografisk träff 2017-05-01

Inhibitor of Tec kinase, LFM-A13, decreases pro-inflammatory mediators production in LPS-stimulated RAW264.7 macrophages via NF-κB pathway.

Wang F, Zhang W, Wang C, Fang X, Cheng H, Liu S, Chen XL.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.16212

Bibliografisk träff 2014-04-26

The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils.

Broides A, Hadad N, Levy J, Levy R.

J Clin Immunol · research support, non-u.s. gov't; journal article · DOI 10.1007/s10875-014-0046-z

Bibliografisk träff 2013-11-13

A pharmacological network for lifespan extension in Caenorhabditis elegans.

Ye X, Linton JM, Schork NJ, Buck LB, Petrascheck M.

Aging Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1111/acel.12163

Bibliografisk träff 2011-01-01

In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.

Uckun F, Dibirdik I, Sarkissian A, Qazi S.

Arzneimittelforschung · meta-analysis; research support, non-u.s. gov't; journal article · DOI 10.1055/s-0031-1296196

Bibliografisk träff 2007-09-26

Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases.

Uckun FM.

Cell Cycle · journal article · DOI 10.4161/cc.6.24.5096

Bibliografisk träff 2007-01-01

Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).

Uckun FM, Tibbles H, Venkatachalam T, DuMez D, Erbeck D.

Arzneimittelforschung · journal article; research support, n.i.h., extramural · DOI 10.1055/s-0031-1296583

Bibliografisk träff 2007-01-01

Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate.

DuMez D, Venkatachalam TK, Uckun FM.

Arzneimittelforschung · journal article; research support, n.i.h., extramural · DOI 10.1055/s-0031-1296599

Bibliografisk träff 2006-10-26

Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).

Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH.

Bioorg Med Chem · journal article · DOI 10.1016/j.bmc.2006.10.050

Bibliografisk träff 2004-05-01

The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.

van den Akker E, van Dijk TB, Schmidt U, Felida L, Beug H, Löwenberg B, von Lindern M.

Biol Chem · research support, non-u.s. gov't; journal article · DOI 10.1515/bc.2004.045

Bibliografisk träff 2004-01-01

In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.

Tibbles HE, Samuel P, Erbeck D, Mahajan S, Uckun FM.

Arzneimittelforschung · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1055/s-0031-1296980

Bibliografisk träff 2003-09-01

The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.

Uckun FM, Vassilev A, Bartell S, Zheng Y, Mahajan S, Tibbles HE.

Leuk Lymphoma · comparative study; journal article · DOI 10.3109/10428190309178781

Bibliografisk träff 2003-05-01

Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor.

Gilbert C, Levasseur S, Desaulniers P, Dusseault AA, Thibault N, Bourgoin SG, Naccache PH.

J Immunol · research support, non-u.s. gov't; journal article · DOI 10.4049/jimmunol.170.10.5235

Bibliografisk träff 2002-05-01

In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.

Uckun FM, Zheng Y, Cetkovic-Cvrlje M, Vassilev A, Lisowski E, Waurzyniak B, Chen H, Carpenter R, Chen CL.

Clin Cancer Res · journal article

Bibliografisk träff 1999-04-01

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].

Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M, Uckun FM.

J Biol Chem · journal article · DOI 10.1074/jbc.274.14.9587